Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 14/20 | 0.50 |
| ▸ | PSMB8 | P28062 | 4/20 | 0.50 |
| ▸ | PSMB9 | P28065 | 3/20 | 0.50 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.50 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.50 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.50 |
| ▸ | PSMA1 | P25786 | 2/20 | 0.50 |
| ▸ | PSMA2 | P25787 | 2/20 | 0.50 |
| ▸ | PSMA3 | P25788 | 2/20 | 0.50 |
| ▸ | PSMA4 | P25789 | 2/20 | 0.50 |
| ▸ | PSMA5 | P28066 | 2/20 | 0.50 |
| ▸ | PSMB4 | P28070 | 2/20 | 0.50 |
| ▸ | PSMB6 | P28072 | 2/20 | 0.50 |
| ▸ | PSMB10 | P40306 | 2/20 | 0.50 |
| ▸ | PSMB3 | P49720 | 2/20 | 0.50 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.50 |
| ▸ | PSMA6 | P60900 | 2/20 | 0.50 |
| ▸ | PSMA8 | Q8TAA3 | 2/20 | 0.50 |
| ▸ | PSMB7 | Q99436 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3110435 | 0.80 | CTRB1 (0.49) | PSMB5PSMB8CTSLCTSBCTSS | |
| SCHEMBL12434741 | 0.78 | PSMB5 (0.39) | PSMB5PSMB8PSMB9PSMB11PSMA7 | |
| SCHEMBL3110340 | 0.77 | CTSS (0.54) | PSMB5PSMB8PSMB9PSMB11PSMA7 | |
| SCHEMBL464437 | 0.76 | PSMB5 (0.54) | PSMB5PSMB8PSMB9PSMB11PSMA7 | |
| SCHEMBL4785463 | 0.75 | CYP1A2 (0.39) | CTSLCA1CA2CA7CTSK | |
| SCHEMBL28574603 | 0.73 | CA12 (0.43) | CTSLCA1CA2CA7CTSB | |
| SCHEMBL22148500 | 0.72 | CTSL (0.40) | CTSLCA1CA2CA7CTSB | |
| SCHEMBL8076514 | 0.72 | PSMB5 (0.45) | PSMB5PSMB8PSMB9PSMB11PSMA7 | |
| SCHEMBL4101793 | 0.71 | GHSR (0.35) | CTSLCTSBCTSSGAA | |
| SCHEMBL17916089 | 0.71 | CTSL (0.37) | CTSLCA1CA2CA7CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200323889-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2020-10-15 | — | — | US | disclosed |
| US-20200046845-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2020-02-13 | — | — | US | disclosed |
| US-20180193486-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180110791-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2018-04-26 | — | — | US | disclosed |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20150005230-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140378414-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140328918-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | CERULEAN PHARMA INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140255374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2014-09-11 | — | — | US | disclosed |
| WO-2013116200-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2013-08-08 | — | — | WO | disclosed |
| EP-2212334-B1 | PROTEASOME INHIBITORS | MILLENNIUM PHARM INC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20120202772-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | GLUCKSMANN ALEXANDRA (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120004195-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2012-01-05 | — | — | US | disclosed |
| US-7838673-B2 | Proteasome inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-7838673-B2 | Proteasome inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-7838673-B2 | Proteasome inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-20090099132-A1 | Proteasome inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099132-A1 | Proteasome inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099132-A1 | Proteasome inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110791-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | PSMB5 18/4885PSMB8 20/4885PSMB9 22/4885 |
| US-20180193486-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | PSMB5 1149/4885PSMB8 1513/4885PSMB9 2085/4885 |
| US-20120202772-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | PSMB5 18/4885PSMB8 20/4885PSMB9 22/4885 |
| US-20120004195-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | PSMB5 18/4885PSMB8 20/4885PSMB9 22/4885 |
| US-20140255374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | PSMB5 1149/4885PSMB8 1513/4885PSMB9 2085/4885 |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | PSMB5 1149/4885PSMB8 1513/4885PSMB9 2085/4885 |
| US-20140328918-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | HLA-DRB1, TSG101, IAPP | PSMB5 650/4885PSMB8 1048/4885PSMB9 963/4885 |
| US-20090099132-A1 | Proteasome inhibitors | PSMB5, PSMG3, PSMB1 | PSMB5 1/4885PSMB8 32/4885PSMB9 37/4885 |
| US-20200323889-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | PSMB5 18/4885PSMB8 20/4885PSMB9 22/4885 |
| US-20200046845-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | PSMB5 1902/4885PSMB8 1933/4885PSMB9 1953/4885 |
| US-20150005230-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | PSMB5 1902/4885PSMB8 1933/4885PSMB9 1953/4885 |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | PSMB5 1902/4885PSMB8 1933/4885PSMB9 1953/4885 |
| US-20140378414-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | PSMB5 18/4885PSMB8 20/4885PSMB9 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.